|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2005-12-20
|
|
pubmed:abstractText |
Advanced prostate cancer responds well to endocrine therapy initially, but soon becomes refractory and has a poor prognosis. We analyzed the prognostic factors of prostate cancer responding well initially to endocrine therapy with lowering of serum prostate specific antigen (PSA) level but later showing PSA relapse.
|
|
pubmed:language |
jpn
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0021-5287
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
96
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
685-90
|
|
pubmed:dateRevised |
2011-7-28
|
|
pubmed:meshHeading |
pubmed-meshheading:16363654-Aged,
pubmed-meshheading:16363654-Aged, 80 and over,
pubmed-meshheading:16363654-Androgen Antagonists,
pubmed-meshheading:16363654-Antineoplastic Agents, Hormonal,
pubmed-meshheading:16363654-Combined Modality Therapy,
pubmed-meshheading:16363654-Gonadotropin-Releasing Hormone,
pubmed-meshheading:16363654-Humans,
pubmed-meshheading:16363654-Male,
pubmed-meshheading:16363654-Middle Aged,
pubmed-meshheading:16363654-Neoplasm Recurrence, Local,
pubmed-meshheading:16363654-Orchiectomy,
pubmed-meshheading:16363654-Prognosis,
pubmed-meshheading:16363654-Prostate-Specific Antigen,
pubmed-meshheading:16363654-Prostatic Neoplasms,
pubmed-meshheading:16363654-Survival Rate
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
[Prognostic factors for PSA relapse of prostate cancer after endocrine therapy].
|
|
pubmed:affiliation |
Department of Urology, Ashikaga Red Cross Hospital.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
